5-MeO-DiPT hýdróklóríð
5-MeO-DiPT hýdróklóríð Verðbil: €23.50 til €336.00
Til baka í vörur
EPT fúmarat (N-etýl-N-própýltryptamín)
EPT fúmarat (N-etýl-N-própýltryptamín) Verðbil: €23.50 til €336.00
5-MeO-DMT freebase - Mynd 1
5-MeO-DMT freebase - Mynd 2

5-MeO-DMT frítt basa

Eiginleikar 5-MeO-DMT fríbasa

Samheiti: 5-metoxý-N,N-dímetýltryptamín
CAS-númer: 1019-45-0
Formúla: 3-[2-(dímetýlamínó)etýl]-5-metoxýindól
Mólmassi: 218,3 g/mól
Hreinleiki: >97%

Verðbil: €25.00 til €700.00

Bæta við til að bera saman
Bæta við óskalista
SPARAÐU 15%

fleiri 2 vörur

SPARA 50%

6 á verði 3

* Upplýsingarnar á þessari síðu eru samantekt og eru ekki ætlaðar til að ná yfir allar tiltækar upplýsingar um þetta lyf. Þær fjalla ekki um alla mögulega notkun, leiðbeiningar, varúðarráðstafanir, milliverkanir lyfja eða aukaverkanir og koma ekki í stað sérfræðiþekkingar og mats heilbrigðisstarfsmanns.

5-MeO-DMT Freebase – Scientific Product Documentation

General Description

5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) freebase is a naturally occurring tryptamine with a potent psychoactive profile, found in various plants and animal secretions. In its freebase form, it offers superior volatility for certain research methods, making it valuable for pharmacological and neuroscience studies.

Tæknilegar upplýsingar

FæribreytaUpplýsingar
Chemical FormulaC₁₃H₁₈N₂O
Molecular Weight218,29 g/mól
Hreinleiki≥98% (HPLC-UV analyzed)
EyðublaðCrystalline/white powder
LeysniSoluble in organic solvents (ethanol, methanol, DMSO), limited in water
Bræðslumark60-65°C (freebase)
StöðugleikiLight and oxygen sensitive; store under inert gas

Vísindaleg notkun

1. Neuropharmacological Research

  • Serotonergic Action:  Potent 5-HT₁ₐ/₂ₐ agonist, relevant for studies of consciousness modulation.

  • EEG/fMRI studies:  Investigation of acute effects on brain wave patterns (e.g. gamma oscillations).

  • Neuroplasticity:  Possible BDNF-enhancing effects (in animal models).

2. Metabolic & Toxicological Studies

  • MAO-dependent metabolism:  Investigation of CYP2D6 and MAO-A degradation pathways.

  • Dose-dependent toxicity:  Determination of safety margins in cell cultures.

3. Comparative Pharmacology

  • Compared to DMT:  Higher potency but shorter duration of action (15-30 min when inhaled).

  • Compared to psilocybin:  Differences in receptor affinity and subjective effects.

Experimental Guidelines

Recommended Concentrations (In Vitro)

UmsóknConcentration rangeLeysiefni
Receptor binding assays1 nM – 10 µMPBS/DMSO (≤0.1%)
Cell culture experiments0.1 – 100 µMDMEM/FBS
Gas chromatography1 mg/ml (in methanol)Methanol (HPLC-grade)

Öryggisreglur

  • Persónuvernd:  Lab coat, nitrile gloves, safety glasses, FFP2 mask when handling powder.

  • Ventilation:  Always work under a fume cupboard when heating/evaporating.

  • Geymsla:  In amber vials, under argon, at -20°C (long term).

Stability & Storage

  • Geymsluþol:

    • Room temperature: <24 hours in solution.

    • 4°C: Stable for 3 days (under argon).

    • -20°C: >6 months (unchanged purity).

  • Degradation products:

    • Oxidation to indole derivatives (check by TLC/HPLC).

Analytical Certification

Each batch includes:

  1. HPLC-UV litrófsgreining  (λ=280 nm, C18 column)

  2. GC-MS confirmation  (characteristic fragments: m/z 174, 160)

  3. Residual solvent analysis  (≤500 ppm)

  4. Water content  (Karl Fischer, <1%)

Lögleg staða (Holland)

  • Opium Act:  Not explicitly regulated, but possibly under analogous legislation.

  • Löggjöf:  A licence is required for scientific institutions (Appendix 2, Opium Act).

  • Export restrictions:  CITES listing (due to natural sources such as  Incilius alvarius ).

Algengar spurningar (FAQ)

Q1: What is the difference between freebase and fumaric acid salt?
A: Freebase is more volatile (suitable for evaporation experiments), while fumaric acid salt is more stable in solutions.

Q2: How is 5-MeO-DFT detected in toxicology screens?
A: Identifiable by:

  • LC-MS/MS (precursor ion m/z 219 → product ion m/z 174)

  • Immunoassays: Cross-reactivity with some DMT tests (≤30%).

Q3: Are there any known pharmacokinetic interactions?
A:  Dangerous combinations:

  • MAO inhibitors (risk of serotonin syndrome).

  • SSRIs (reduced efficacy due to competition).

Q4: How to dispose of waste?
A: Inactivate with:

  1. Dilute hydrochloric acid (0.1M) for neutralization.

  2. Absorption with activated carbon.

  3. Dispose of as  hazardous chemical waste  (UN number: 3249).

References & Contact

Key publications:

  • Szára, S. (2007). “DMT and 5-MeO-DMT: Early human studies”.

  • Uthaug et al. (2021). “Psychopharmacology of 5-MeO-DMT”.

This product is intended solely for legitimate scientific research. Not for human or veterinary use. Users must comply with all local regulations.